top of page

Addressing challenges of innovative cancer immunotherapy medicines

The European Medicines Agency’s (EMA) Committee for Advanced Therapies (CAT) is organising a workshop on 15 and 16 November 2016 to discuss scientific and regulatory challenges of immunotherapy medicines based on genetically modified T-cells (white blood cells that normally fight off viruses and bacteria).

Click on this link for more information.


Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page